Patients UK-wide whole genome sequencing for newborns is feasible - b... Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year ann
Views & Analysis How to balance the patient voice atop the shifting plates of... The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm?
Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis Deep Dive: Market Access It’s fair to say this is the most interesting time ever for market access.
Market Access Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaph... Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitti
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.